DCGI approved AstraZeneca’s Lynparza as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer

AstraZeneca India, a leading science-led biopharmaceutical company, today announced that it has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2-…